Eagle Pharmaceuticals, Inc. (EGRX)
OTCMKTS
· Delayed Price · Currency is USD
0.750
-0.150 (-16.67%)
Nov 13, 2024, 9:30 AM EST
Eagle Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2017 - 2013 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '23 Jun 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2017 - 2013 |
| Revenue | 257.55 | 316.61 | 171.55 | 187.8 | 195.89 | 213.31 | Upgrade
|
| Revenue Growth (YoY) | -5.38% | 84.56% | -8.66% | -4.13% | -8.17% | -9.88% | Upgrade
|
| Cost of Revenue | 77.68 | 94.94 | 42.18 | 45.47 | 60.9 | 61.92 | Upgrade
|
| Gross Profit | 179.88 | 221.67 | 129.37 | 142.34 | 135 | 151.4 | Upgrade
|
| Selling, General & Admin | 102.52 | 87.13 | 75.32 | 78.6 | 76.37 | 60.51 | Upgrade
|
| Research & Development | 35.65 | 34.09 | 51.28 | 30.79 | 36.81 | 44.42 | Upgrade
|
| Operating Expenses | 138.17 | 121.21 | 126.6 | 109.38 | 113.18 | 104.93 | Upgrade
|
| Operating Income | 41.71 | 100.46 | 2.77 | 32.95 | 21.82 | 46.47 | Upgrade
|
| Interest Expense | -6.09 | -4.05 | -1.64 | -2.58 | -2.69 | -2.74 | Upgrade
|
| Interest & Investment Income | 0.28 | 0.27 | 0.56 | 0.56 | 2.17 | 0.16 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.61 | -10.33 | -0.76 | - | 0.7 | - | Upgrade
|
| EBT Excluding Unusual Items | 32.29 | 86.35 | 0.94 | 30.94 | 22 | 43.89 | Upgrade
|
| Merger & Restructuring Charges | -1.3 | -12.6 | - | - | - | -10.62 | Upgrade
|
| Gain (Loss) on Sale of Investments | -2.42 | -5.42 | -5.48 | -8.26 | - | - | Upgrade
|
| Other Unusual Items | 0.6 | -6.9 | - | - | - | 0.76 | Upgrade
|
| Pretax Income | 29.17 | 61.43 | -4.55 | 22.68 | 22 | 34.04 | Upgrade
|
| Income Tax Expense | 17.22 | 25.79 | 4.08 | 10.69 | 7.69 | 2.14 | Upgrade
|
| Net Income | 11.95 | 35.64 | -8.63 | 11.99 | 14.31 | 31.9 | Upgrade
|
| Net Income to Common | 11.95 | 35.64 | -8.63 | 11.99 | 14.31 | 31.9 | Upgrade
|
| Net Income Growth | -47.57% | - | - | -16.24% | -55.14% | -38.58% | Upgrade
|
| Shares Outstanding (Basic) | 13 | 13 | 13 | 13 | 14 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 13 | 13 | 13 | 14 | 14 | 15 | Upgrade
|
| Shares Change (YoY) | 2.21% | 0.11% | -5.23% | -2.60% | -7.46% | -3.96% | Upgrade
|
| EPS (Basic) | 0.91 | 2.76 | -0.66 | 0.89 | 1.04 | 2.16 | Upgrade
|
| EPS (Diluted) | 0.91 | 2.73 | -0.66 | 0.87 | 1.01 | 2.09 | Upgrade
|
| EPS Growth | -48.44% | - | - | -13.86% | -51.67% | -36.09% | Upgrade
|
| Free Cash Flow | -9.39 | 50.52 | 27.9 | 48.75 | 55.21 | 52.25 | Upgrade
|
| Free Cash Flow Per Share | -0.71 | 3.87 | 2.14 | 3.54 | 3.90 | 3.42 | Upgrade
|
| Gross Margin | 69.84% | 70.01% | 75.41% | 75.79% | 68.91% | 70.97% | Upgrade
|
| Operating Margin | 16.19% | 31.73% | 1.61% | 17.55% | 11.14% | 21.78% | Upgrade
|
| Profit Margin | 4.64% | 11.26% | -5.03% | 6.38% | 7.31% | 14.96% | Upgrade
|
| Free Cash Flow Margin | -3.65% | 15.96% | 16.26% | 25.96% | 28.18% | 24.50% | Upgrade
|
| EBITDA | 62.33 | 112.48 | 6.53 | 36.49 | 25.31 | 50.14 | Upgrade
|
| EBITDA Margin | 24.20% | 35.53% | 3.81% | 19.43% | 12.92% | 23.50% | Upgrade
|
| D&A For EBITDA | 20.62 | 12.02 | 3.76 | 3.54 | 3.49 | 3.67 | Upgrade
|
| EBIT | 41.71 | 100.46 | 2.77 | 32.95 | 21.82 | 46.47 | Upgrade
|
| EBIT Margin | 16.19% | 31.73% | 1.61% | 17.55% | 11.14% | 21.78% | Upgrade
|
| Effective Tax Rate | 59.04% | 41.98% | - | 47.13% | 34.93% | 6.27% | Upgrade
|
| Revenue as Reported | 257.55 | 316.61 | 171.55 | 187.8 | 195.89 | 213.31 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.